DiaMedica Therapeutics (DMAC) Receivables (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Receivables for 10 consecutive years, with $480000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 58.42% year-over-year to $480000.0; the trailing twelve-month figure through Jun 2026 stood at $480000.0 (up 58.42% YoY), and the FY2025 full-year result was $508000.0, up 114.35% from the prior year.
• Receivables retreated to $480000.0 in Q2 2026 per DMAC's latest filing, from $586000.0 in the prior quarter.
• Across five years, Receivables topped out at $790000.0 in Q1 2024 and bottomed at $75000.0 in Q3 2022.
• Historically, Receivables has averaged $425611.1 across 5 years, with a median of $481000.0 in 2025.
• The widest YoY moves for Receivables: up 725.33% in 2023, down 66.47% in 2023.
• Over 5 years, Receivables stood at $162000.0 in 2022, then jumped by 311.73% to $667000.0 in 2023, then sank by 64.47% to $237000.0 in 2024, then surged by 114.35% to $508000.0 in 2025, then decreased by 5.51% to $480000.0 in 2026.
• According to Business Quant data, Receivables over the past three periods registered $480000.0, $586000.0, and $508000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.